Skip to main content

Rabbit Recombinant Monoclonal FGF19 antibody. Suitable for WB, IHC-P and reacts with Human samples.

Be the first to review this product! Submit a review

Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829), expandable thumbnail
  • Western blot - Anti-FGF19 antibody [EPR29017-89] (AB320829), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (AB320829), expandable thumbnail

Key facts

Isotype
IgG
Host species
Rabbit
Storage buffer

pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Form
Liquid
Clonality
Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Abcam Recommends

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
WBIHC-P
Human
Tested
Tested

Tested
Tested

Species
Human
Dilution info
1/1000
Notes

-

Tested
Tested

Species
Human
Dilution info
1/2000
Notes

Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Target data

Function

Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4.

Alternative names

Recommended products

Rabbit Recombinant Monoclonal FGF19 antibody. Suitable for WB, IHC-P and reacts with Human samples.

Key facts

Isotype
IgG
Form
Liquid
Clonality
Monoclonal
Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number
EPR29017-89
Purification technique
Affinity purification Protein A
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

FGF19 also known as fibroblast growth factor 19 is a 251 amino acid protein with a molecular mass of approximately 27 kDa. It is mostly expressed in the liver small intestine and to some extent in the gallbladder. FGF19 is related to the FGF family of growth factors which are involved in a variety of developmental and physiological processes. Unlike many other FGF members FGF19 lacks a heparin-binding domain which influences its receptor binding characteristics. Researchers frequently use FGF19 ELISA kits and FGF19 assays to study this protein due to its significance in regulating bile acid metabolism.

Biological function summary

Fibroblast growth factor 19 participates in maintaining metabolic homeostasis and controlling bile acid synthesis. It acts by binding to a receptor complex composed of FGFR4 and beta-Klotho which signals the regulation of energy balance and interaction with other metabolic targets. FGF19 protein triggers pathways that modulate glucose and lipid metabolism making it an important factor in metabolic health. Its regulation of lipid and glucose processes emphasizes its role in metabolic control systems and potential impacts on obesity and diabetes management.

Pathways

The fibroblast growth factor 19 engages in two critical signaling routes: the MAPK/ERK and the PI3K/AKT pathways. These pathways are fundamental in cell proliferation differentiation and survival. FGF19 through FGFR4 activation influences regulatory proteins and factors downstream bridging interactions with other key molecules such as insulin and leptin pathways. This regulatory mechanism contributes to its ability to fine-tune a wide range of metabolic functions and influences energy balance.

Associated diseases and disorders

Fibroblast growth factor 19 shows a significant connection to non-alcoholic fatty liver disease (NAFLD) and certain forms of cancer. Altered expression levels of FGF19 associate with liver conditions due to its role in bile acid regulation and energy homeostasis. In cancer particularly hepatocellular carcinoma the dysregulation of FGF19 and its receptor plays a part in unchecked cellular proliferation and tumorigenesis. Researchers have noted connections with proteins such as FGFR4 and beta-Klotho highlighting their collaborative roles in disease progression and potential therapeutic targeting strategies.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

6 product images

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829)

    Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Negative control: no staining on human liver (PMID: 31976601).

    The section was incubated with ab320829 for 30 mins at room temperature.

    The immunostaining was performed on a Leica Biosystems BOND® RX instrument

    Counterstained with Hematoxylin.

    Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829)

    Immunohistochemical analysis of paraffin-embedded (A) SW480 (human colorectal adenocarcinoma epithelial cell) cell pellet; (B) HL-60 (human acute promyelocytic leukemia promyeloblast) cell pellet tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Positive staining on (A) SW480 cell pellet; no staining on (B) HL-60 cell pellet.

    The section was incubated with ab320829 for 30 mins at room temperature.

    The immunostaining was performed on a Leica Biosystems BOND® RX instrument

    Counterstained with Hematoxylin.

    Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829)

    Immunohistochemical analysis of paraffin-embedded Human gall bladder tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Positive staining on epthelium of human gall bladder (PMID: 26256900).

    The section was incubated with ab320829 for 30 mins at room temperature.

    The immunostaining was performed on a Leica Biosystems BOND® RX instrument

    Counterstained with Hematoxylin.

    Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

  • Western blot - Anti-FGF19 antibody [EPR29017-89] (ab320829), expandable thumbnail

    Western blot - Anti-FGF19 antibody [EPR29017-89] (ab320829)

    Blocking and diluting buffer and concentration: 5% NFDM/TBST.

    Negative control: HL-60, HeLa, K-562, 293T (PMID: 10525310)

    In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.

    All lanes: Western blot - Anti-FGF19 antibody [EPR29017-89] (ab320829) at 1/1000 dilution

    Lane 1: SW480 (human colorectal adenocarcinoma epithelial cell) whole cell lysate at 20 µg

    Lane 2: COLO1 (human colon adenocarcinoma tumor ascitic fibroblast-like cell) whole cell lysate at 20 µg

    Lane 3: HL-60 (human acute promyelocytic leukemia promyeloblast) whole cell lysate at 20 µg

    Lane 4: HeLa (human cervical adenocarcinoma epithelial cell) whole cell lysate at 20 µg

    Lane 5: K-562 (human chronic myelogenous leukemia lymphoblast) whole cell lysate at 20 µg

    Lane 6: 293T (human embryonic kidney epithelial cell) whole cell lysate at 20 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution

    Observed band size: 24 kDa, 36 kDa

    Exposure time: 37s

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829)

    Immunohistochemical analysis of paraffin-embedded Human colon tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Negative control: no staining on human colon (PMID: 37345586, 36923538).

    The section was incubated with ab320829 for 30 mins at room temperature.

    The immunostaining was performed on a Leica Biosystems BOND® RX instrument

    Counterstained with Hematoxylin.

    Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGF19 antibody [EPR29017-89] (ab320829)

    Immunohistochemical analysis of paraffin-embedded Human endometrial carcinoma tissue labeling FGF19 with ab320829 at 1/2000 (0.254 ug/ml) dilution, followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Positive staining on human endometrial carcinoma.

    The section was incubated with ab320829 for 30 mins at room temperature.

    The immunostaining was performed on a Leica Biosystems BOND® RX instrument

    Counterstained with Hematoxylin.

    Secondary antibody only control: Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection).

    Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com